Vir Biotechnology: Promising Hepatitis B Treatment Data Amid Cautious Optimism and Awaited Milestones
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) on November 15 and set a price ...
Is It Too Late to Buy Viking Therapeutics Stock?
Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...
Business Insider19h
Promising Clinical Trial Results and Future Potential Justify Buy Rating for Akero Therapeutics
Ulz covers the Healthcare sector, focusing on stocks such as Silence Therapeutics, Viking Therapeutics, and IO Biotech. According to TipRanks, Ulz has an average return of 2.7% and a 40.66% success ...